The seed oil of Paeonia ludlowii ameliorates Aß25-35-induced Alzheimer's disease in rats.

Paeonia ludlowii, a plant of the Paeoniaceae family, has abundant genetic diversity in different populations, and the seed oil can be used in a diverse number of activities. However, its neuroprotective effect is not clear. We investigated the memory-improving effects and associated mechanisms of Paeonia ludlowii seed oil (PLSO) on amyloid beta (Aß)25-35-induced Alzheimer's disease (AD) in rats. The Morris water maze test was undertaken, and subsequently, the content of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), and acetylcholinesterase (ACHE) in the hippocampus was detected by biochemical analyses. To further study PLSO, we examined the pathologic structure and apoptosis of hippocampal tissue by staining. Immunohistochemical analysis was used to detect expression of IBA-1 and GFAP in the hippocampus. Detection of proinflammatory factors was achieved by reverse transcription-quantitative polymerase chain reaction and Western blotting. High-dose PLSO inhibited expression of GFAP and IBA-1. We demonstrated that high-dose PLSO can regulate activation of glial cells and mediate apoptosis of hippocampal cells, and significantly improve learning and memory deficits in AD rats. PLSO could be developed as a nutritional supplement and sold as a drug for AD prevention and/or treatment.

Psychological morbidity and health-related quality of life in patients with differing awareness of cancer diagnosis: a cross-sectional study.

OBJECTIVE: Concealment of cancer diagnosis from patients is not rare worldwide and physicians in mainland China are in fact discouraged from disclosing a cancer diagnosis to cancer patients. Preventing worsened psychological morbidity is at the core of the argument for nondisclosure. The purpose of this study was to quantify anxiety, depression, and distress among patients with various degrees of awareness of their cancer diagnosis. Quality of life was also measured. METHODS: Using a cross-sectional and blinded design, the Hospital Anxiety and Depression Scale questionnaire, the Distress Thermometer, and the SF-36 Health Survey were administered to 287 hospitalized patients with oral and maxillofacial tumors. Independently, the patients' awareness of disease was assessed with semistructured interviews. RESULTS: Hospital Anxiety and Depression Scale, Distress Thermometer, and SF-36 did not identify significant differences in scores among the hospitalized patients with various degrees of awareness of their cancer diagnosis: an awaiting diagnosis group, a concealed diagnosis group, and a disclosed diagnosis group. CONCLUSIONS: Before surgery, inpatients who were hospitalized because of oral and maxillofacial tumors with various degrees of awareness of their cancer diagnosis had similar psychological morbidity and quality of life. Informing hospitalized cancer patients of their diagnosis before surgery may not deteriorate their psychiatric condition or their quality of life.

When clinicians telling the truth is de facto discouraged, what is the family's attitude towards disclosing to a relative their cancer diagnosis?

PURPOSE: This study evaluated the attitudes of cancer patients' family members regarding disclosure of a cancer diagnosis to the patient and justifications for their attitudes. METHODS: Family members were invited to complete a questionnaire to evaluate their attitudes towards disclosure of a cancer diagnosis to a relative as well as reasons for their point of view. Data were analyzed to evaluate factors influencing attitudes. RESULTS: One hundred eighty-six completed surveys were returned. Of them, 44.1 % (82/186) indicated that the patient should be informed of the diagnosis, and 55.9 % (104/186) stated emphatically that the patient should not be told the truth. The main reason given for concealing the truth was fear that awareness of a cancer diagnosis might cause psychological morbidity. The justifications for disclosing the bad news were as follows: (1) obtaining the patient's cooperation during treatment, (2) the impossibility of concealment, and (3) believing the patient was psychologically strong enough to accept the truth. Patients' educational status and awareness of disease as well as family members' age were the factors that influenced attitudes toward disclosure. CONCLUSIONS: Telling the truth to a cancer patient is often de facto discouraged in clinicians. Family members often support nondisclosure, especially when they have experience with a relative who is unaware of the truth. The education level of family members does not appear to influence decisions regarding disclosure. These findings can be helpful in the development of policies and/or programs to assist medical professionals and family members engage in truthful disclosure to a patient who has cancer.

Is therapeutic non-disclosure still possible? A study on the awareness of cancer diagnosis in China.

OBJECTIVE: The objectives are to study cancer patients' awareness of their diagnosis and to determine who tends to disclose bad news to cancer patients. METHOD: A total of 151 consecutive oral and maxillofacial cancer patients and their relatives were surveyed using semi-structured interviews. RESULTS: Of the 151 patients, 64.2% were aware of their cancer diagnosis. Of this group, 20.6% had been told by physicians and 17.5% were informed by relatives, with the remaining 61.9% acquiring the diagnosis on their own. The more educated patients were more likely to be aware they had cancer. CONCLUSION: Despite efforts by family members to conceal cancer diagnoses from patients, the majority of patients discovered the diagnosis of their own accord. This finding suggests that therapeutic non-disclosure is not very effective at withholding the truth from patients.